Elanco Animal Health's GAAP net income for 3 months of 2022 was $48 million, compared to a loss of $61 million in the previous year. Revenue decreased by 1.4% to $1.225 billion from $1.242 billion a year earlier.

Elanco Animal Health's GAAP loss for 2021 was $472 million, down 15.7% from $560 million the previous year. Revenue increased 45.6% to $4.765 billion from $3.273 billion a year earlier.

FDA has approved Elanco's Zorbium post-operative cat anesthetic. One dose of the drug is effective for up to four days. The first batch of Zorbium will arrive at veterinary clinics in mid-2022.

Elanco Animal Health's GAAP loss for 9M 2021 was $375 million, up 58.2% from $237 million in the prior year. Revenues increased 71.1% to $3.652 billion from $2.134 billion a year earlier.